StockNews.AI
EW
StockNews.AI
123 days

Eight-Year Data Confirm Long-Term Durability of Edwards' RESILIA Tissue

1. Edwards Lifesciences announces improved long-term outcomes for RESILIA tissue valves. 2. The eight-year data reinforces Edwards' leadership in heart valve innovation.

2m saved
Insight
Article

FAQ

Why Bullish?

The positive outcome data for RESILIA valves supports growth potential. Historical performance shows similar announcements typically lead to price upticks.

How important is it?

The data signifies competitive advantage in a critical product line, crucial for investor interest.

Why Long Term?

Sustained improvements in patient outcomes can lead to increased market share over time, boosting future revenue.

Related Companies

ABTMDTSNN
CAIRO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary RESILIA tissue technology have significantly improved long-term outcomes compared to those receiving non-RESILIA tissue bioprosthetic valves. For more than 65 years, Edwards has been the leader in heart valve innovations. To create a more durable heart valve, Edwards developed the RESILIA tissue technology more than two d.

Related News